Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Absence of Pharmacokinetic Interactions between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate.

Jones NS, Winter H, Katsumoto TR, Florero M, Murray E, Walker H, Singh N, Chinn LW.

J Pharmacol Exp Ther. 2019 Oct;371(1):202-207. doi: 10.1124/jpet.119.257089. Epub 2019 Aug 1.

2.

Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.

Herman AE, Chinn LW, Kotwal SG, Murray ER, Zhao R, Florero M, Lin A, Moein A, Wang R, Bremer M, Kokubu S, Serone AP, Hanze EL, Viberg A, Morimoto AM, Winter HR, Katsumoto TR.

Clin Pharmacol Ther. 2018 Jun;103(6):1020-1028. doi: 10.1002/cpt.1056. Epub 2018 Mar 23.

PMID:
29484638
3.

Impact of multiple lymphatic channel drainage to a single nodal basin on outcomes in melanoma.

Wall JK, Florero M, Accortt NA, Allen R, Kashani-Sabet M, Morita E, Leong SP.

Arch Surg. 2007 Aug;142(8):753-7; discussion 756-8.

PMID:
17709729

Supplemental Content

Loading ...
Support Center